Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs ING Groep NV — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while ING Groep NV trades at $33.34 (market cap $94.92B). The key difference: ING Groep NV is far larger — about 3.1× GE HealthCare Technologies Inc. Common Stock's market cap, and ING Groep NV pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| GEHC | ING | |
|---|---|---|
Market Cap | $31.07B | $94.92B |
Volume | 3,443,020 | 2,055,666 |
Sector | Health | Financials |
52-Week High | $88.16 | $37.27 |
52-Week Low | $59.48 | $23.66 |
Enterprise Value | $39.53B | $237.77B |
Dividend Yield | 0.23% | 3.93% |
Typical Hold Time | — | 94 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
ING trades at $33.46, up 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue reached $22.90 billion in 2025, with a net income margin of 28.34%. Analyst sentiment is positive, with 11 buy ratings and no sell ratings among 17 analysts. Recent news highlights an upgraded ROE target above 16% for 2027 and strategic focus on organic growth.
The outlook for ING is cautiously optimistic, supported by earnings momentum and favorable analyst coverage. Key opportunities include revenue growth and profitability targets, while risks involve persistent negative operating cash flows and regulatory scrutiny, such as recent capital requirements in Australia. The stock's valuation metrics, including a P/E of 12.99, suggest reasonable pricing relative to earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
